- Home
- TBI vs MOLN Comparison
TBI vs MOLN Comparison
Compare TBI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- MOLN
- Stock Information
- Founded
- TBI 1985
- MOLN 2004
- Country
- TBI United States
- MOLN Switzerland
- Employees
- TBI N/A
- MOLN N/A
- Industry
- TBI Professional Services
- MOLN
- Sector
- TBI Consumer Discretionary
- MOLN
- Exchange
- TBI Nasdaq
- MOLN Nasdaq
- Market Cap
- TBI 165.9M
- MOLN 142.5M
- IPO Year
- TBI 1996
- MOLN 2021
- Fundamental
- Price
- TBI $4.72
- MOLN $4.05
- Analyst Decision
- TBI Buy
- MOLN Hold
- Analyst Count
- TBI 1
- MOLN 1
- Target Price
- TBI $8.00
- MOLN $4.00
- AVG Volume (30 Days)
- TBI 267.2K
- MOLN 1.9K
- Earning Date
- TBI 11-03-2025
- MOLN 10-30-2025
- Dividend Yield
- TBI N/A
- MOLN N/A
- EPS Growth
- TBI N/A
- MOLN N/A
- EPS
- TBI N/A
- MOLN N/A
- Revenue
- TBI $1,534,863,000.00
- MOLN N/A
- Revenue This Year
- TBI $2.21
- MOLN N/A
- Revenue Next Year
- TBI $6.18
- MOLN $1,000.00
- P/E Ratio
- TBI N/A
- MOLN N/A
- Revenue Growth
- TBI N/A
- MOLN N/A
- 52 Week Low
- TBI $3.45
- MOLN $3.36
- 52 Week High
- TBI $9.05
- MOLN $6.24
- Technical
- Relative Strength Index (RSI)
- TBI 28.85
- MOLN 59.87
- Support Level
- TBI $5.28
- MOLN $3.63
- Resistance Level
- TBI $5.98
- MOLN $3.77
- Average True Range (ATR)
- TBI 0.24
- MOLN 0.14
- MACD
- TBI -0.09
- MOLN 0.01
- Stochastic Oscillator
- TBI 10.28
- MOLN 43.70
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.